Lexicon Pharmaceuticals, Inc.
http://www.lexpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Lexicon Pharmaceuticals, Inc.
ESMO 24: CDK2 Inhibitors - Where Next For The Novel Class?
The Barcelona meeting saw early data from two candidates from Incyte and Pfizer which suggest some progress for a new drug mechanism that has so far underwhelmed.
Finance Watch: Follow-Ons Bring In Big Post-Data Cash For Nuvalent And Others
Public Company Edition: Follow-on public offerings brought in $500m for Nuvalent, $235m for Summit and $225m each for Centessa and Viridian after recent readouts. Also, Kairos raised $6.2m in this year’s 19th IPO, Bayer sold €750m ($834m) in bonds and an Ionis FOPO grossed $500.3m.
ESMO 24: Nuvation One Step Ahead In Race For ROS1 Lung Cancer Niche
Two similarly named companies, Nuvation and Nuvalent, are racing to see who can claim best-in-class status in next-generation lung cancer therapies.
They’re Back! US FDA Panels Return To Normal And The Schedule Fills Up Fast
The US FDA is returning to the pre-COVID in-person advisory committee format and the agency suddenly has a flood of meetings lined up for the fall.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice